1![NOMINATION FORM FOR MPN HEROES NOMINATION FORM FOR MPN HEROES NOMINATION FORM FOR MPN HEROES NOMINATION FORM FOR MPN HEROES](https://www.pdfsearch.io/img/dd9804e8859ec1837d3cb0cb55a05acb.jpg) | Add to Reading ListSource URL: curemagazine.s3.amazonaws.comLanguage: English - Date: 2015-07-10 15:12:35
|
---|
2![1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62 1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62](https://www.pdfsearch.io/img/5e000f1924516a92c3a01c63a72d7835.jpg) | Add to Reading ListSource URL: whobluebooks.iarc.frLanguage: English - Date: 2015-10-29 10:08:25
|
---|
3![1 Dr James Vardiman Professor Emeritus Department of Pathology University of Chicago 1 Dr James Vardiman Professor Emeritus Department of Pathology University of Chicago](https://www.pdfsearch.io/img/65346681a52747428d52a4991311888a.jpg) | Add to Reading ListSource URL: whobluebooks.iarc.frLanguage: English - Date: 2015-10-29 10:08:25
|
---|
4![Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No) Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No)](https://www.pdfsearch.io/img/99b8a5ad823af76c0302cf4682a2d04a.jpg) | Add to Reading ListSource URL: www.shirecanada.comLanguage: English - Date: 2016-03-02 15:52:12
|
---|
5![Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No) Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No)](https://www.pdfsearch.io/img/07571bb178c846fd642cbbf712611ae5.jpg) | Add to Reading ListSource URL: www.shirecanada.comLanguage: English - Date: 2016-03-02 15:52:12
|
---|
6![Amgen version datedHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. x Amgen version datedHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. x](https://www.pdfsearch.io/img/23819312fb02809e611dc6f402971c77.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2009-09-18 15:51:15
|
---|
7![Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard](https://www.pdfsearch.io/img/6478b55422631656af8fae0f81bdcf6d.jpg) | Add to Reading ListSource URL: www.promedior.comLanguage: English - Date: 2015-02-08 17:25:15
|
---|
8![Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca](https://www.pdfsearch.io/img/78414298a37a920cf1bd331896515f57.jpg) | Add to Reading ListSource URL: www.novartis.caLanguage: English - Date: 2015-05-13 10:22:06
|
---|
9![Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre](https://www.pdfsearch.io/img/a4d21164024a2142e2bf1bab3912113e.jpg) | Add to Reading ListSource URL: www.promedior.comLanguage: English - Date: 2014-06-13 01:07:42
|
---|
10![___________________ CONTRAINDICATIONS ___________________ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing infor ___________________ CONTRAINDICATIONS ___________________ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing infor](https://www.pdfsearch.io/img/5e216b25675c3ff056891976d2f911a8.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2014-12-04 17:30:23
|
---|